The Efficacy of Pre-Treatment Proton Pump Inhibitors in the Eradication of Helicobacter pylori

Öz

Objective: Proton pump inhibitors significantly reduce Helicobacter pylori colonization and provide recovery in its activity and inflammation. We investigated; the effects of eradication initiated 28 days after proton pump inhibitor treatment and eradication initiated simultaneously with proton pump inhibitor treatment, on treatment success rates of Helicobacter pylori. Material and Methods: The study took place at our tertiary care hospital, where 42 patients in the study group were given oral lansoprazole treatment for 28 days followed by eradication treatment and 41 patients in the control group were given both treatments simultaneously. Eradication success was monitored using Helicobacter pylori polyclonal antigen stool tests. Results: A total of 83 participants, aged between 8 and 18 years, tested positive for Helicobacter pylori. The mean age of the participants was 15.14 ± 2.01 years. The Helicobacter pylori cure rate was found to be 92.9% in the study group and 92.7% in the control group. There were no significant differences observed between the two groups in terms of eradicating Helicobacter pylori (p=0.976). Conclusion: We found no significant differences in Helicobacter pylori treatment success rates with modified proton pump inhibitor usage in children.

Anahtar Kelimeler

• Esophagogastroduodenoscopy
• Helicobacter pylori
• Proton pump inhibitors
• Treatment

Helicobacter pylori Eradikasyonunda Tedavi Öncesi Proton Pompa İnhibitörlerinin Etkinliği

Öz

Amaç: Proton pompa inhibitörleri Helicobacter pylori kolonizasyonunu önemli ölçüde azaltarak aktivitesinde ve inflamasyonda azalma sağlar. Proton pompası inhibitörü tedavisinden 28 gün sonra başlatılan eradikasyonun ve proton pompası inhibitörü tedavisiyle eş zamanlı başlatılan eradikasyonun Helicobacter pylori tedavi başarı oranlarına etkisini araştırdık. Gereç ve Yöntemler: Araştırma, üçüncü basamak tedavi merkezi olan hastanemizde gerçekleştirildi; burada çalışma grubundaki 42 hastaya 28 gün boyunca oral lansoprazol tedavisi ve ardından eradikasyon tedavisi verildi, kontrol grubundaki 41 hastaya ise her iki tedavi aynı anda verildi. Eradikasyon başarısı Helicobacter pylori poliklonal antijen dışkı testi kullanılarak değerlendirildi. Bulgular: Çalışmamıza yaşları 8 ile 18 arasında değişen ve Helicobacter pylori pozitif olan toplam 83 katılımcı dahil edildi. Katılımcıların ortalama yaşı 15.14±2.01’di. Helicobacter pylori iyileşme oranı çalışma grubunda %92.9, kontrol grubunda ise %92.7 olarak bulundu. Helicobacter pylori’nin eradikasyonu açısından iki grup arasında anlamlı bir fark gözlenmedi (p=0.976). Sonuç: Çocuklarda modifiye proton pompa inhibitörü kullanımı ile Helicobacter pylori tedavisi başarı oranlarında anlamlı bir fark bulunamadı.

Anahtar Kelimeler

• Özofagogastroduodenoskopi
• Helicobakter pylori
• Proton pompa inhibitörleri
• Tedavi

Kaynakça

1. Quaglia NC, Dambrosio A. Helicobacter pylori: A foodborne pathogen? World J Gastroenterol 2018;24:3472-87.
2. Floch P, Mégraud F, Lehours P. Helicobacter pylori Strains and Gastric MALT Lymphoma. Toxins (Basel) 2017;9:132.
3. Jones, NL, Koletzko S, Goodman K, Bontems P, Cadranel S, Casswall T, et al. Joint ESPGHAN/NASPGHAN guidelines for the management of Helicobacter pylori in children and adolescents (update 2016). J Pediatr Gastroenterol Nutr 2017;64:991-1003
4. Kaplan M, Tanoglu A, Duzenli T, Tozun AN. Helicobacter pylori treatment in Turkey: Current status and rational treatment options. North Clin Istanb 2019;7:87-94.
5. Mišak Z, Hojsak I, Homan M. Review: Helicobacter pylori in pediatrics. Helicobacter 2019;24 Suppl 1:e12639.
6. Graham DY, Lee YC, Wu MS. Rational Helicobacter pylori therapy: evidence-based medicine rather than medicine-based evidence. Clin Gastroenterol Hepatol 2014;12:177-86.e3; Discussion e12-3.
7. Thung I, Aramin H, Vavinskaya V, Gupta S, Park JY, Crowe SE, Valasek MA. Review article: the global emergence of Helicobacter pylori antibiotic resistance. Aliment Pharmacol Ther 2016;43:514-33.
8. Caliskan R, Tokman HB, Erzin Y, et al. Antimicrobial resistance of Helicobacter pylori strains to five antibiotics, including levofloxacin, in Northwestern Turkey. Rev Soc Bras Med Trop 2015;48:278-84.

9. Scott DR, Sachs G, Marcus EA. The role of acid inhibition in Helicobacter pylori eradication. F1000Res 2016;5:F1000 Faculty Rev-1747.
10. Gong EJ, Kim DH, Ahn JY, Na HK, Jung KW, Lee JH, et al. Effects of Proton Pump Inhibitor on the Distribution of Helicobacter pylori and Associated Gastritis in Patients with Gastric Atrophy. Digestion 2020;101:279-86.
11. Moayyedi P, Wason C, Peacock R, Walan A, Bardhan K, Axon AT, Dixon MF. Changing patterns of Helicobacter pylori gastritis in long-standing acid suppression. Helicobacter 2000;5:206-14.
12. Dixon MF, Genta RM, Yardley JH,Correa P. Classification and grading of gastritis. The updated Sydney System. International Workshop on the Histopathology of Gastritis, Houston 1994. Am J Surg Pathol 1996;20:1161–81.
13. Shinozaki S, Osawa H, Sakamoto H, Hayashi Y, Kobayashi Y, Miura Y, et al. Pre-treatment with proton pump inhibitors decreases the success of primary Helicobacter pylori eradication using a vonoprazan-based regimen. Kaohsiung J Med Sci 2018;34:456-60.
14. Janssen MJ, Laheij RJ, Jansen JB, de Boer WA. The influence of pretreatment on cure rates of Helicobacter pylori eradication. Neth J Med 2004;62:192-6.
15. Yuan Y, Ford AC, Khan KJ, Gisbert JP, Forman D, Leontiadis GI, et al. Optimum duration of regimens for Helicobacter pylori eradication. Cochrane Database Syst Rev 2013;12:CD008337
16. Malfertheiner P, Megraud F, O’Morain CA, Gisbert JP, Kuipers EJ, Axon AT, et al. Management of Helicobacter pylori infection-the Maastricht V/Florence Consensus Report. Gut 2017;66:6‐30
17. Labenz J. Current role of acid suppressants in Helicobacter pylori eradication therapy. Best Pract Res Clin Gastroenterol 2001;15:413-31.
18. Kuang S, Xu J, Chen M, Zhang Y, Shi F, Lu X. The influence of pretreatment with PPI on Helicobacter pylori eradication: A systematic review and meta-analysis. Medicine (Baltimore) 2021;100:e27944.
19. Çelebi A, Aydın D, Kocaman O, Konduk BT, Şentürk Ö, Hülagü S. Comparison of the effects of esomeprazole 40 mg, rabeprazole 20 mg, lansoprazole 30 mg, and pantoprazole 40 mg on intragastrıc pH in extensive metabolizer patients with gastroesophageal reflux disease. Turk J Gastroenterol 2016;27:408-14.
20. Szőke A, Mocan S, Negovan A. Helicobacter pylori infection over bile reflux: No influence on the severity of endoscopic or premalignant gastric lesion development. Exp Ther Med 2021;22:766.
21. Agin M, Kayar Y. The Effect of Primary Duodenogastric Bile Reflux on the Presence and Density of Helicobacter pylori and on Gastritis in Childhood. Medicina (Kaunas) 2019;55:775.